Reported 1 day ago
Ascentage Pharma Group International, a leading biotech firm, has raised approximately $192.3 million through an oversubscribed offshore share placement, involving the issuance of 22 million ordinary shares at a price of HKD68.60 each. The shares were offered by the Dajun Yang Dynasty Trust, associated with CEO Dr. Dajun Yang, targeting non-U.S. investors. The new equity will make up about 6.29% of the company's total share capital, enhancing its capacity to develop therapies for various diseases.
Source: YAHOO